Curve pattern in Glenmark pharma

Dee the result of last similar formation highlighted in the chart.

İşlem aktif:

Glenmark Pharma reported better than expected EBITDA and EBITDA margin.

· Q1 net profit Rs254cr (up 132% YoY) – expectation Rs144cr,

· Ebitda Rs478cr (up 40% YoY) – expectation Rs372cr,

· EBITDA margin 20.4% vs 14.5% (YoY) – expectation 14.8%

· Income Rs Rs2345cr (up 1% YoY)- expectation Rs2515cr